Market News & Updates
Stay informed with useful updates from markets, mutual funds, and investor awareness initiatives.
24 Aug 2026
Hy-Tech Engineers IPO opens today: GMP signals 47% listing premium. Should you subscribe?
Hy-Tech Engineers IPO: The Rs 135.73-crore issue set to remain open until August 27. The IPO comprises a fresh issue of Rs 60 crore and an OFS worth Rs 75.73 crore. Its GMP currently signals a potential 47% listing premium, indicating strong investor interest. Allotment is expected on August 28, with listing tentatively scheduled for September 1.
Read More
24 Aug 2026
Symbiotec Pharmalab’s Rs 1,757 crore IPO opens with GMP hinting at 41% upside. Should you bid?
Symbiotec Pharmalab IPO GMP: Symbiotec Pharmalab’s Rs 1,757 crore IPO opened August 24, with a Rs 938–988 price band and 41% grey-market premium. The issue combines fresh shares and an OFS, while proceeds will partly repay debt. Its specialised API manufacturing, regulatory approvals and biotechnology capabilities offer investors exposure to India’s pharmaceutical manufacturing growth.
Read More
24 Aug 2026
IPO rush continues: 10 issues to raise over Rs 3,500 crore this week
This week sees the launch of six mainboard IPOs and four from the SME sector, with total fundraising expected to surpass Rs 3,500 crore. Among these, Symbiotec Pharmalab's IPO stands out as the largest, aiming for substantial investment. The market is buzzing with other companies also set for their stock market introductions, ensuring a robust IPO pipeline this month.
Read More
24 Aug 2026
Can Symbiotec Pharmalab IPO deliver long-term growth for high-risk investors?
Symbiotec Pharmalab plans a ₹150 crore IPO to repay debt and expand operations. The company holds a global leadership position in corticosteroid and steroidal-hormone APIs. Its revenue primarily comes from international markets, with Europe being a significant contributor. Financials show steady revenue and EBITDA growth over recent years. Investors with a high-risk appetite may consider this long-term opportunity.
Read More
24 Aug 2026
Tempsens Instrument IPO: GMP soars past 100%, signalling strong listing hopes
Tempsens Instruments IPO grey market premium has surged 100 percent. This marks the first IPO to cross this milestone in nearly two years. The IPO was subscribed nearly 22 times on its second day. Other upcoming IPOs also show strengthening grey market premiums. Investor appetite for new share sales appears to be reviving.
Read More
23 Aug 2026
Pride Hotels steps up expansion, plans Rs 1,000-cr IPO by December
The expansion has taken Pride Hotels' portfolio to 40 properties, including eight owned hotels and 32 managed properties. The company has also signed contracts for another 32 hotels, which are expected to open over the next one-and-a-half to two years, taking its portfolio to about 72 properties.
Read More
23 Aug 2026
Rs 3,300 crore IPO week: Symbiotec, Skyways Air to lead 10-offer rush for investors
India's IPO market is set for a busy week, with 10 companies, including Symbiotec Pharmalab, Skyways Air Services, Hy-Tech Engineers and Lumino Industries, looking to raise over Rs 3,300 crore. Mainboard IPOs will be accompanied by five SME issues, while grey market premiums point to strong investor interest in several upcoming offerings.
Read More
22 Aug 2026
Freedom Oils maker Gemini Edibles & Fats India files DRHP with Sebi for IPO
Gemini Edibles & Fats India, maker of Freedom Oils, filed IPO papers with Sebi for an entirely offer-for-sale issue of up to 4.12 crore shares. Promoters and investors will sell stakes, while the company earns no proceeds. Revenue rose to Rs 12,650 crore in FY26, supported by strong branded oil growth.
Read More
22 Aug 2026
Mom's Belief operator to launch IPO on Sep 1
On September 1, Rays of Belief Ltd will make its debut in the stock market with an initial public offering. With ambitious plans to open 319 new centers across India by FY29, the IPO proceeds will support expansion efforts, including fit-outs and technological advancements. The company aims to enhance neurodevelopmental care in Tier-II and Tier-III cities while showcasing impressive revenue growth.
Read More